The W 3 gene encodes a novel zinc-finger protein that shares homology with several Drosophila transcription factors. This gene was identified by its disruption in translocations involving chromosome 3q27 in diffuse large-cell lymphomas. To assess the frequency and role of this gene's involvement in lymphomagenesis and tumor progression, we examined a series of 170 cases of non-Hodgkin's lymphomas of B-cell lineage for LA23 gene rearrangement, expression, and mutation. The cases included 35 de novo diffuse aggressive lymphomas (DAL; 19 large-cell, 4 mixed-cell, and 12 large-cell immunoblastic), 52 transformed aggressive lymphomas derived from follicular lymphomas (TFL), 42 indolent follicular lymphomas (FL), 14 mantle cell lymphomas (MCL), and 27 small noncleaved cell lymphomas (SNCL). LA23 rearrangements were found in 10 DAL (28.6461, 9 TFL (17.3%). and 6 FL (14.346). but not in any of the SNCL or MCL. LA23 rearrangement was not exclusive of bcl-2 rearrangement. Most rearrangement breakpoints mapped t o a 10-kb BamHI-Xba I fragment located 5' t o the LA23 coding sequence, consistent with previously reported breakpoint locations. Northern analysis of both rearranged and nonre--CELL LYMPHOMAS contain characteristic molecular abnormalities involving important cellular genes that frequently participate in cell cycle processes and growth. ' The most extensively investigated of these B-cell "oncogenes" are the BCL-2 gene implicated in follicular l y m p h~m a ,~.~ the c-MYC gene in Burkitt's lymph~ma,'.~ and CCNDl (BCL-1PRADl) in mantle cell lymphoma?-9 These genes were identified through their rearrangement into the Ig gene locus. The rearrangements are believed to result in transcriptional deregulation either through the disruption of the gene's own regulatory signals or by placing the gene under the control of the Ig regulatory regions." For some of these genes, further mutation involving coding sequences does not seem to be common; however, for others (eg, c-MYC), additional mutations within critical sequences occur and may further deregulate the The LAZ3 gene,I3.I4 also named BCL-6I5.l6 or BCL-5," is the most recent of the B-cell-associated candidate oncogenes to be cloned through its association with the Ig locus. This gene is located on chromosome 3q27 and encodes a novel zinc-finger protein that shares homology with several Drosophila transcription factors, including the Drosophila tramtrack and Broad-complex genes.I4 Its function is unknown. Rearrangement of LAZ3 can involve either of the Ig light chain genes or the Ig heavy chain locus on chromosomes 22q12,2p12, and 14q23. By analogy with other protooncogenes that become juxtaposed to the Ig gene loci through translocation, deregulation of the LA23 gene is believed to result, at least in part, from its proximity to the Ig gene enhancer elements. The LAZ3 breakpoints generally occur just 3' to the first exon, allowing for the possibility that loss of endogenous regulatory signals may also play a role in this gene's deregulation." B-cell lymphomas with LAZ3 rearrangement have been shown to express L a 3 m-RNA; however, there have been no studies comparing arranged B-cell lymphoma cases showed similar levels of a transcript of approximately 3.8 kb, indicating that LA23 is broadly expressed in B-cell tumors and is not confined t o rearranged cases. To investigate whether mutation of the W 3 gene might contribute t o a potential role for this gene in lymphomagenesis, we screened the coding sequences of 13 rearranged cases, 6 nonrearranged cases, and 13 hematopoietic tumor cell lines. Although three probable polymorphisms were identified, mutations were detected in only 2 rearranged cases. Only 1 of these resulted in an amino acid substitution. Two cell lines (SU-DHL4 and Molt-4) also contained mutations; only one resulted in an amino acid substitution. We conclude (1) that W 3 rearrangements occur in a significant fraction of de novo DAL as well as ih a smaller subset of indolent and transformed follicular lymphomas; (2) that LA23 message is expressed in both rearranged and nonrearranged B-cell lymphomas; and (3) that mutation of the LA23 gene does not contribute to its putative oncogenic role in most 3q27 translocated B-cell lymphomas. 0 1995 by The American Society of Hematology.
expression levels in rearranged and nonrearranged lymphomas. Furthermore, the potential role of coding region mutations as a component of LAZ3 deregulation is unknown.
LAZ3 rearrangement has been reported in a relatively high proportion (>30%) of diffuse large-cell lymphomas.'9s20 It has been suggested to be relatively specific for large-cell lymphomas that occur de novo, ie, without a preceding indolent lymphoma stage, and to define a bcl-2-independent pathway of lymphomagenesis. However, there are contradictory data regarding the frequency of its involvement in other types of lymphoma, particularly in bcl-2 carrying indolent follicular lymphomas and in transformed follicular lymphomas. [18] [19] [20] To better understand the role of LAZ3 involvement in B-cell lymphomagenesis, we studied a series of 170 wellcharacterized B-cell lymphomas for rearrangement of this putative oncogene. Northern blot analysis was performed on a subset of 37 rearranged and nonrearranged cases to study the consequences of the rearrangement on gene expression.
To determine whether mutation of the LAZ3 coding sequences might contribute to LAZ3 deregulation, we also analyzed rearranged cases by single-strand conformation polymorphism (SSCP), followed by sequencing of abnormal conformers.
Our data indicate that LAZ3 rearrangements occur at highest frequency in de novo aggressive lymphomas and at lower frequency in indolent and transformed follicular lymphomas, with or without concomitant bcl-2 involvement. Our data also indicate that levels of RNA expression are variable in rearranged cases and are not significantly higher than in nonrearranged cases. Finally, mutation of the LAZ3 gene product does not contribute to its putative oncogenic role in 3q27-translocated B-cell lymphomas.
MATERIALS AND METHODS
Cases studied. A total of 170 lymphoid tumor samples of Bcell lineage from patients observed at the National Institutes of Health were selected for this study, based on the availability of frozen tissue for molecular analysis. These samples included 35 de novo diffuse aggressive lymphomas (DAL: 19 diffuse large-cell, 4 diffuse mixed, and 12 diffuse large-cell immunoblastic); 47 indolent, low-grade follicular lymphomas (E); 52 transformed follicular lymphomas (TIT); 14 mantle cell lymphomas (MCL); and 27 small noncleaved cell lymphomas (SNCL). A biopsy was considered to represent a transformed follicular lymphoma if histologically it was classified as an intermediate-grade or high-grade lymphoma according to the criteria of the Working Formulation for Clinical Usage*' and if the patient had biopsy documented evidence of a preceding or coincident indolent follicular lymphoma. The B-cell lineage of all cases was confirmed by flow cytornetry and/or immunohistochemistry and by Ig gene rearrangements. These analyses also served to insure that there was a sufficient percentage of tumor cells present for analysis of LA23 rearrangement. The majority of patient materials used in this study are from patients enrolled in clinical studies and have been provided informed consent according to the guidelines of the Institutional Review Board of the National Institutes of Health.
DNA exrruction and Southern blot analysis. High molecular weight DNA was extracted from frozen tissue samples or cell suspensions using a standard phenokhloroform extraction procedure as previously described." After restriction enzyme digestion with BarnHI, Xba I, EcoRI, or HindIII, the DNA was size-fractionated by agarose gel electrophoresis and transferred onto nylon membranes (Gene Screen Plus; New England Nuclear Research Products, Boston, MA). The filters were sequentially hybridized with randomprimed "P-labeled probes for 20 to 24 hours at 42°C and washed under stringent conditions, according to the recommendations of the supplier. Autoradiographs were developed after 1 to 7 days.
RNA extraction and Northern blot analysis. Thirty-seven primary lymphoma samples (including 13 of the 24 rearranged cases) and 15 hematologic cell lines of various lineages were studied by Northern blot analysis. Total cellular RNA was extracted using RNA-zol (Biotecx Laboratories, Inc, Houston, TX), according to the manufacturer's instructions. Fifteen micrograms of RNA was loaded per lane, electrophoresed through 1 % formaldehyde-agarose gel, and transferred to nylon membranes (Gene Screen Plus). Hybridizations and autoradiography were performed as described above for the Southern blot analysis.
Probes. LA23 rearrangement was assessed using a previously described genomic 2.3-kb BurnHI-Xho I intron l fragment, F372,I3 whereas a l-kb EcoRI cDNA fragment derived from clone M55 was used in the Northern blot analyses." BCL-2 involvement was examined with a battery of three probes (bcl-2: pfl-2:' and pB16") designed to screen for rearrangement of the major breakpoint region (MBR), the minor cluster region (MCR), and a second minor breakpoint cluster located 5' to exon 1 (5' MCR). Ig gene rearrangement was assessed with probes to JH and JK. A probe to glyceraldehyde 3-phosphate dehydrogenase (GAPDH) was used for assessing equal loading of RNA in the Northern blot analysis. The Ig and bcl-2 probes were gifts from Dr S. Korsmeyer (Washington University School of Medicine, St Louis, MO), the pfl-2 probe was a gift from Dr M. Cleary (Stanford University School of Medicine, Stanford, CA), and the pB16 probe was a gift from Dr G. Tsujimoto (Osaka University Medical School, Osaka, Japan). The GAPDH probe was purchased from the American Tissue Culture Collection (ATCC; Rockville, MD).
cDNA synthesis. One microgram of total RNA and 50 ng of random hexamer oligodeoxyribonucleotides in 13 pL was heated to 70°C for 10 minutes followed by cooling on ice for 1 minute. cDNA synthesis was initiated using 200 U of Superscript I1 RNase Hreverse transcriptase (GIBCO BRL Life Technologies, Gaithersburg, MD), under conditions recommended by the manufacturer, and the reaction was allowed to proceed at 42°C for 50 minutes. The reaction was terminated by heating at 70°C for 15 minutes.
SSCP. SSCP analysis was performed according to a modified version of a previously reported pr0cedure.2~ Oligonucleotide primers were synthesized by the solid-phase triester method. Fifteen sets of primers, defining overlapping cDNA sequences, were designed to screen the complete LA23 coding region, as reported previo~sly.'~ The sequences of the primers are as follows: primer set no. I After an initial denaturation at 95°C for 5 minutes, 35 cycles of denaturation (94°C for I minute), annealing (60°C for 1 minute). and extension (70°C for 1 minute) were performed on a DNA thermal cycler 480 (Perkin Elmer Cetus, Norwalk, CT). The final extension was performed for 7 minutes. An aliquot of each reaction mixture was diluted as described previously. 26 Samples were loaded onto a 6% acrylamide gel containing 10% glycerol. To obtain optimal separation of the single-stranded conformers, the ratio of methylene-bis-acrylamide to acrylamide generally used was either 1:99 or 1:19. Gel electrophoresis was performed at 8 W for 12 to 15 hours or at 40 W for 5 to 7 hours. Autoradiogra-(5-5; 5"TGAGGAGTITCGGGATGTCC-3', 5-3: 5"CTGGCC-7 (7-5, 5"AGAAGAGGCACGAAGTGATA-3', 7-3; 5"AGITGG-(9-5; 5"GTCCTGCAGCAGTAAGAATG-3', 9-3; 5"GTGTAG-CTGAGCAG-3', 10-3; 5"CATGTAGAGTGGTGAGTGGC-3'), GAGATGGGAGAGAC-3'. 12-3; 5"GTTGCAACGATAGGG-CGTGCCCATGTGCTTATCCA-3', 14-3; 5"ACGCGGTATTGC-ACTTG-3', 15-3; 5"ACCCCCACCACCCACAACCC-3'). phy was performed using an intensifying screen and an exposure of 4 to 60 hours at -70°C. Sequencing strategy. To confirm the presence of a mutation, direct sequencing was performed using the Sequenase PCR Product Sequencing Kit (US Biochemical Corp. Cleveland. OH), according to the instructions supplied by the manufacturer. Briefly, S to 30 pg of the reamplified PCR product was treated with I U of Exonuclease I and 2 U of Shrimp Alkaline Phosphatase at 37°C for IS minutes to remove excess primers. After heat inactivation of the added enzymes, 0.2 to 0.5 pmol of the PCR product was used as a template for sequencing. The denatured, single-stranded product was annealed with 10 pmol of the appropriate primer, and the sequencing reaction was performed using "S-dATP. Autoradiographs were developed after 1 to 10 days of exposure at ambient temperature. of the lymphomas studied and indicating that the biopsies contained a sufficient proportion of tumor cells for subsequent studies.
RESULTS

Southern
LAZ3 rearrangement was detected in 25 of 170 cases (14.7%: Table 1 and Fig l ) . The highest incidence was found in the de novo diffuse aggressive lymphoma group in which IO of 35 cases (28.6%) showed rearrangement. In this group, rearrangements were found in all of the included histologic subtypes: S of 19 (29.4%) diffuse large-cell lymphomas, 2 of 4 (50%) diffuse mixed lymphomas, and 3 of 12 (25%) diffuse large-cell immunoblastic lymphomas showed rearrangement. LAZ3 involvement was not limited to the de novo DAL group because rearangements were also present in 6 of 42 low-grade follicular lymphomas (l4.3%), and 9 of S2 transformed lymphomas (TFL: 17.3%) that evolved from follicular lymphomas. None of the 27 SNCL or 14 MCL showed LAZ3 rearrangement.
The LAZ3 breakpoints were mapped using four different restriction enzymes as described in the Materials and Methods. These clustered in a IO-kb RamHI-Xha I fragment located S' to the LAZ3 coding sequences in intron I , as shown in Fig 2, consistent with previously reported breakpoint locations.''.'* Correlarion between LA23 rearrangement and RCL-2 gene status. Because LAZ3 rearrangements were initially described in de novo diffuse large-cell and diffuse immunoblastic lymphomas and, in initial studies, had been reported to be rare in follicular lymphomas, we wished to evaluate the relationship between BCL-2 rearrangement and LAZ3 rearrangement. The BCL-2 gene rearrangement status was evaluated in a majority of the DAL, FL, and TFL cases and is shown in Table 2 . LAZ3 gene rearrangements occurred in 30% (3/10) of BCL-2-rearranged DAL and in 23% (5/22) of BCL-2-negative DAL. In the combined FL and TFL cases, LAZ3 rearrangements occurred in 14.9% of BCL-2-rearranged cases (1 1/74) and in 26.7% of BCL-2-nonrearranged cases (4/1S).
Northern blot onalyis. Thirteen LAZ3-rearranged cases and 24 nonrearranged cases were screened for LAZ3 expression by Northern blot analysis. Levels of RNA expression were variable in both rearranged and nonrearranged cases and the range of expression was not appreciably higher in rearranged cases (Fig 3) . All rearranged cases showed a transcript of approximately 3.8 kb, the size reported for the normal LAZ3 tran~cript.'~"' A larger transcript of approximately 11 kb was seen in one of the nonrearranged cases (DL24). This may represent a partially, or alternatively, spliced form of the LAZ3 message. These results suggest that LAZ3 gene rearrangement does not significantly alter mRNA expression levels, nor does it grossly affect message size.
To study the range of expression in hematopoietic neoplasms, a panel of 14 hematopoietic cell lines consisting of several lineages were also examined. As shown in PCR-SSCP analysis and sequencing of abnormal conformers. To investigate whether mutation of the LAZ3 gene might contribute to a potential role for this gene in lymphomagenesis, we screened the coding sequences of 13 rearranged cases, 6 nonrearranged cases, and 13 tumor cell lines.
Several probable polymorphisms were uncovered in this analysis. A repetitive pattern of abnormal conformers was found in primer sets 8 (Fig 5B) , 11, and 13. A conservative T to C substitution at codon 415 was found to be responsible for the abnormality in primer set 8. The two alleles were found at a frequency of 60.5% and 39.5%, respectively, in the cases studied. A consistent G to A substitution was also found at codon 521 at a frequency of 78.9% and 21.1%, respectively. This change resulted in the replacement of the "normal" Ala by a Thr (GCT to ACT). There was no difference in the frequency of the two alternate alleles in rearranged cases, in nonrearranged cases, or in the cell lines, suggesting that this substitution is likely to be a polymorphism and unrelated to LAZ3 rearrangement. Finally, a conservative C to T substitution was found in primer set 13 at codon 632 at a frequency of 92.9% and 7.1%, respectively. Of the three probable polymorphisms identified, only the one at codon 521 affected the coding sequence.
Only two rearranged cases, DL23 and TFL25, displayed abnormal SSCP patterns outside of the above polymorphic sites. In case DL23, the abnormal conformer present in the primer set 2 SSCP product (Fig 5A) was found to be the result of a G to A transition at codon 76 (Fig 6A) . This mutation did not affect the amino acid residue. In case TFL25, the abnormally migrating conformer in primer set 3 (Fig 5C) was found to be the result of a G to T transversion that resulted in the replacement of the normal glutamine at codon 192 by an aspartic acid residue.
Two cell lines (SU-DHLA and Molt4; Fig 5D and E, respectively) were also found to have abnormal conformers in the SSCP analysis. The mutation in SU-DHLA (Fig 6B) occurred within primer set 15 and proved to be a mutation 3' to the stop codon. The mutation in Molt4 occurred in primer set 7. Sequence analysis of this abnormal conformer revealed a mutation at codon 349 that resulted in the substitution of a valine for an alanine (GCA to GTA; Ala to Val). Thus, it does not appear that mutations are common in the LAZ3 coding sequence. Note that all cases show a transcript of about 3.8 kb, that levels of expression are variable in both rearranged and nonrearranged cases, and that the range of expression is similar in rearranged and nonrearranged cases. A larger hybridizing band of about 11 kb can be seen in one nonrearranged case (DL24).
DISCUSSION
and the subset of aggressive lymphomas that arise from follicular lymphomas, the situation has not been clear, with one Translocations involving the LAZ3 gene at chromosome group reporting an incidence of in follicular lymph om as^^) 3q27 have been primarily associated with diffuse aggressive and another group an incidence of about 130/o.~~) lymphomas* and it has recently been repofled that as many In the present study, we have identified LAZ3 gene reas 30% to 40% of these lymphomas have breakpoints that arrangements in 28.6% of DAL. This incidence is slightly cluster into the first intron of this gene.'"'" With regard to lower than the 37% reported by Bastard et ally and the 33% other lymphoma subtypes, particularly follicular lymphomas, reported by Lo Coco et al. 20 The reason for our lower inci- dence may reflect the fact that our series does not include cytogenetically proven index cases that could lead to an overrepresentation of LAZ3-rearranged cases. Alternatively, our lower numbers may simply represent geographic differences in pathogenesis or institutional selection criteria.
In the low-grade follicular lymphoma group, we found an incidence of 14.3%. This result is similar to that previously reported by Bastard et al." Our transformed follicular lymphomas showed a similar incidence of 17.3%. Of 11 transformed follicular lymphomas in which the preceding low-grade follicular lymphoma was available. for molecular studies, two were LAZ3 rearranged. In both cases, the indolent lymphoma biopsies possessed the identical rearrangement as the subsequent transformed lymphomas. Taken together, these data indicate that LAZ3 rearrangement is not temporally associated with progression. This is unlike the situation for acquired MYC rearrangements or acquired mutations of the p53 tumor suppressor gene, in which the Thr -Thr acquisition of these abnormalities is temporally correlated with histologic However, it is still possible that the presence of LAZ3 rearrangement may influence the rate at which progression occurs, and prospective studies of LAZ3-rearranged follicular lymphomas will be necessary to address this possibility.
It has been suggested that LAZ3 rearrangement and BCL-2 rearrangement may define two distinct and independent pathogenetic pathways in B-cell lymphoma^.'^.^" Our data indicating that a significant percentage of follicular lymphomas possessed LAZ3 rearrangements suggested that these two abnormalities were unlikely to be exclusive. Analysis of BCL-2 rearrangement in these cases indicated that LAZ3 rearrangement was present in both BCL-2 nonrearranged and rearranged lymphomas. Thus, these two molecular lesions do not appear to be exclusive of each other.
Our comparative analysis of LAZ3 expression levels in rearranged and nonrearranged cases showed no obvious correlation between LAZ3 gene rearrangement and the degree of RNA expression. Rearrangement of LAZ3 does not lead to high steady-state levels of expression in all cases, and some nonrearranged cases and nonrearranged cell lines may show relatively high expression levels. Furthermore, the size of the transcript in the rearranged cases is not obviously different from that of the normal 3.8-kb message. Thus, although we could not show a clear effect of the rearrangement on gene expression, we believe that a subtle but critical deregulation of gene expression is still a likely result of the rearrangement. This could occur through the loss andor gain of regulatory sequences 5' to the breakpoints, in a manner analogous to c-MYC rearrangement in Burkitt's lymphoma. 6 Alternatively, because the location of the translocation within intron 1 predicts an altered transcript, it is possible that some transcripts, while appearing to be of normal size, may represent fusion products between LAZ3 and another gene, either Ig, in the case of the t(3; 14) translocation, or other unknown genes in the variant translocations (J.P. Kerckaert, personal communication, June 1994).
To acquire additional information regarding the potential mechanisms by which LAZ3 might contribute to lymphomagenesis, we also examined the LAZ3 coding region for mutations in our rearranged cases. Because we had previously identified functionally active mutations in the coding region of the c-MYC gene in t(8; 14) rearranged aggressive lymphowe wondered, by analogy, whether similar, functionally active mutations could occur in the LAZ3 gene as a result of its proximity to one of the Ig gene loci. Further stimulating our interest in this possibility was the fact that one of the three published cDNA sequences" showed several sequence differences from the other two.I4." However, our comprehensive analysis of 13 rearranged tumors and several additional tumor lines showed that mutation of LAZ3 is rare and therefore unlikely to contribute its deregulation. This conclusion assumes that the RT-PCR product analyzed is representative of the tumor cells and not from contaminating normal cells. We believe that this is a reasonable assumption because most of the tumors were composed of greater than 70% tumor cells and because the major contaminating populations of normal cells are reactive B and T cells that produce very little LAZ3 message.
The SSCP analysis also uncovered several probable polymorphisms, at codons 415, 521, and 632, that may prove useful for genetic studies. None of these was at the sites of the originally reported sequence discrepancies. Additional studies of normal tissues are needed to confirm these nucleotide differences as polymorphisms.
In summary, we have identified LAZ3 rearrangements in a significant percentage of follicular and transformed follicular lymphomas, as well as in a high percentage of de novo diffuse aggressive lymphomas. This rearrangement occurred mas,' I . 29.30 independently of the presence of BCL-2 involvement. We have also found that the range of LAZ3 message expression is similar in rearranged and nonrearranged B-cell lymphomas, suggesting that the oncogenic effect of LAZ3 may not simply be related to its absolute level in the rearranged cases. Finally, we have failed to identify mutations within the coding sequences of a large number of rearranged cases studied, indicating that alteration of the biologic activities of LAZ3 through mutation is not a common mechanism responsible for its oncogenic activity.
